JP2013527762A5 - - Google Patents

Info

Publication number

JP2013527762A5

JP2013527762A5 JP2013508501A JP2013508501A JP2013527762A5 JP 2013527762 A5 JP2013527762 A5 JP 2013527762A5 JP 2013508501 A JP2013508501 A JP 2013508501A JP 2013508501 A JP2013508501 A JP 2013508501A JP 2013527762 A5 JP2013527762 A5 JP 2013527762A5

Authority

JP

Japan

Prior art keywords

seq

antibody

fragment

variable region

chain variable

Prior art date

2011-05-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims 104
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 26
• 206010028980 Neoplasm Diseases 0.000 claims 12
• 201000011510 cancer Diseases 0.000 claims 10
• 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims 7
• 102000055436 human LRP6 Human genes 0.000 claims 7
• 102000005962 receptors Human genes 0.000 claims 7
• 108020003175 receptors Proteins 0.000 claims 7
• 102000013814 Wnt Human genes 0.000 claims 6
• 108050003627 Wnt Proteins 0.000 claims 6
• 239000003814 drug Substances 0.000 claims 6
• 102000039446 nucleic acids Human genes 0.000 claims 6
• 108020004707 nucleic acids Proteins 0.000 claims 6
• 150000007523 nucleic acids Chemical class 0.000 claims 6
• 102000004169 proteins and genes Human genes 0.000 claims 6
• 108090000623 proteins and genes Proteins 0.000 claims 6
• 230000004156 Wnt signaling pathway Effects 0.000 claims 4
• 102000052547 Wnt-1 Human genes 0.000 claims 4
• 108700020987 Wnt-1 Proteins 0.000 claims 4
• 230000002401 inhibitory effect Effects 0.000 claims 4
• 230000001404 mediated effect Effects 0.000 claims 4
• 239000002773 nucleotide Substances 0.000 claims 4
• 125000003729 nucleotide group Chemical group 0.000 claims 4
• 229920001184 polypeptide Polymers 0.000 claims 4
• 102000004196 processed proteins & peptides Human genes 0.000 claims 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
• 206010005003 Bladder cancer Diseases 0.000 claims 3
• 206010006187 Breast cancer Diseases 0.000 claims 3
• 208000026310 Breast neoplasm Diseases 0.000 claims 3
• 102000006259 LDL-Receptor Related Proteins Human genes 0.000 claims 3
• 108010058141 LDL-Receptor Related Proteins Proteins 0.000 claims 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
• 208000034578 Multiple myelomas Diseases 0.000 claims 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
• 206010033128 Ovarian cancer Diseases 0.000 claims 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
• 206010060862 Prostate cancer Diseases 0.000 claims 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
• 102000023732 binding proteins Human genes 0.000 claims 3
• 108091008324 binding proteins Proteins 0.000 claims 3
• 206010017758 gastric cancer Diseases 0.000 claims 3
• 201000007270 liver cancer Diseases 0.000 claims 3
• 208000014018 liver neoplasm Diseases 0.000 claims 3
• 201000005202 lung cancer Diseases 0.000 claims 3
• 208000020816 lung neoplasm Diseases 0.000 claims 3
• 201000001441 melanoma Diseases 0.000 claims 3
• 201000008968 osteosarcoma Diseases 0.000 claims 3
• 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
• 201000011549 stomach cancer Diseases 0.000 claims 3
• 201000005112 urinary bladder cancer Diseases 0.000 claims 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
• 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
• 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
• 102000052549 Wnt-3 Human genes 0.000 claims 2
• 108700020985 Wnt-3 Proteins 0.000 claims 2
• 238000003556 assay Methods 0.000 claims 2
• 229940079593 drug Drugs 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• 230000002708 enhancing effect Effects 0.000 claims 2
• 238000000338 in vitro Methods 0.000 claims 2
• 230000037361 pathway Effects 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 230000011664 signaling Effects 0.000 claims 2
• 238000004448 titration Methods 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 230000001684 chronic effect Effects 0.000 claims 1
• 238000010494 dissociation reaction Methods 0.000 claims 1
• 230000005593 dissociations Effects 0.000 claims 1
• 210000004602 germ cell Anatomy 0.000 claims 1
• 239000003446 ligand Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 208000025113 myeloid leukemia Diseases 0.000 claims 1
• 230000026731 phosphorylation Effects 0.000 claims 1
• 238000003566 phosphorylation assay Methods 0.000 claims 1
• 238000006366 phosphorylation reaction Methods 0.000 claims 1